U.S. Markets open in 1 hr 38 mins

Pharmaxis Ltd (PXS.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.27-0.01 (-3.57%)
At close: 4:10PM AEST
Full screen
Previous Close0.28
Open0.28
Bid0.27 x 1978400
Ask0.28 x 682600
Day's Range0.27 - 0.28
52 Week Range0.23 - 0.31
Volume62,578
Avg. Volume218,613
Market Cap86.32M
BetaN/A
PE Ratio (TTM)-4.66
EPS (TTM)-0.06
Earnings DateMar 1, 2016 - Mar 5, 2016
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.08
  • PR Newswire26 days ago

    Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

    Pharmaxis to receive €18 million milestone payment in a significant further endorsement of the company's ability to generate value from its early stage pipeline. INGELHEIM, Germany and SYDNEY, Aug. 25, 2017 /PRNewswire/ -- Boehringer Ingelheim and pharmaceutical company Pharmaxis (PXS.AX) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

  • PR Newswire26 days ago

    Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

    Pharmaxis to receive €18 million milestone payment in a significant further endorsement of the company's ability to generate value from its early stage pipeline. INGELHEIM, Germany and SYDNEY, Aug. 24, 2017 /PRNewswire/ -- Boehringer Ingelheim and pharmaceutical company Pharmaxis (PXS.AX) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

  • Pharmaxis Ltd. :PXS-AU: Earnings Analysis: For the six months ended June 30, 2017 : August 14, 2017
    Capital Cubelast month

    Pharmaxis Ltd. :PXS-AU: Earnings Analysis: For the six months ended June 30, 2017 : August 14, 2017

    Categories: Yahoo FinanceGet free summary analysis Pharmaxis Ltd. reports financial results for the half-year ended June 30, 2017. Highlights Summary numbers: Revenues of AUD 7.45 million, Net Earnings of AUD -7.31 million. Gross margins narrowed from 26.13% to -3.80% compared to the same period last year, operating (EBITDA) margins now -129.03% from -64.92%. Earnings rose compared to ... Read more (Read more...)